Page 1 of 74
NSG 533 ADVANCED PHARMACOLOGY EXAM 1WITH
VERIFIED ANSWERS DETAILED RATIONALES GRADED A+
NSG 533 Advanced Pharmacology Exam 1
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1–45)
1. A 68-year-old patient with heart failure and atrial fibrillation is being started on digoxin.
The nurse practitioner considers the patient's renal function because digoxin is primarily
eliminated renally. Which pharmacokinetic parameter is most directly affected by reduced
renal clearance, thereby increasing the risk of digoxin toxicity?
A. Volume of distribution
B. Hepatic metabolism
C. Elimination half-life
D. Protein binding
Rationale: C. Digoxin is excreted predominantly unchanged by the kidneys. Reduced renal
clearance prolongs the elimination half-life, causing drug accumulation and increased risk of
toxicity.
2. Which pharmacokinetic process is primarily affected by a patient's serum albumin levels?
A. Metabolism
B. Absorption
C. Distribution
D. Excretion
1|Page
,Page 2 of 74
Rationale: C. Distribution involves the transport of a drug by the bloodstream to its site of
action. Many drugs bind to plasma proteins like albumin, and only the unbound portion is
pharmacologically active. If albumin levels are low, the concentration of free drug increases,
potentially leading to toxicity.
3. When a drug is an inducer of the Cytochrome P450 (CYP) enzyme system, what is the most
likely clinical outcome for a co-administered substrate?
A. Prolonged half-life of the substrate drug
B. Increased plasma levels of the substrate drug
C. Decreased plasma levels of the substrate drug
D. Decreased rate of metabolism for the substrate drug
Rationale: C. Enzyme induction involves the stimulation of CYP enzymes, which increases the
metabolic capacity of the liver. This results in faster breakdown of substrate drugs, leading to
lower plasma concentrations and potentially subtherapeutic effects.
4. A drug with a high therapeutic index (TI) is generally considered:
A. Potentially toxic at standard doses
B. Relatively safe
C. Likely to cause significant side effects
D. Highly potent
Rationale: B. The therapeutic index is a ratio that compares the blood concentration at which
a drug becomes toxic to the concentration at which it is effective. A high therapeutic index
indicates a wide margin of safety between the therapeutic and lethal doses.
5. Which of the following describes a drug that binds to a receptor and produces a maximal
biological response?
A. Full Agonist
B. Antagonist
C. Partial Agonist
D. Inverse Agonist
Rationale: A. A full agonist binds to a receptor and produces a maximal biological response. A
2|Page
,Page 3 of 74
partial agonist produces a lower response, and an antagonist blocks the receptor without
activating it.
6. Pharmacokinetics is best defined as the study of:
A. The study of drug effects on the body; receptor binding, signal transduction, response, and
feedback
B. The study of drug movement throughout the body; absorption, distribution, metabolism, and
excretion
C. The study of drug toxicity; accumulation, sensitivity, idiosyncrasy, and tolerance
D. The study of drug interactions; potentiation, antagonism, synergism, and displacement
Rationale: B. Pharmacokinetics is derived from the Greek words "pharmakon" (drug) and
"kinesis" (motion). It encompasses the four basic processes of absorption, distribution,
metabolism, and excretion (ADME).
7. A 65-year-old male with chronic kidney disease (eGFR 30 mL/min) is prescribed a
medication that is primarily renally excreted. Which pharmacokinetic parameter is most
affected in this patient?
A. Bioavailability
B. Volume of distribution
C. Half-life
D. Onset of action
E. Protein binding
Rationale: C. Renal impairment directly affects drug excretion, leading to prolonged half-lives
and drug accumulation. Dose adjustments are often required.
8. A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (CL) of 50 L/hr. Which
of the following best describes the expected half-life (t½) and the clinical implication of such a
large Vd?
A. t½ = 5 hours
B. t½ = 10 hours
C. t½ = 7 hours
3|Page
, Page 4 of 74
D. t½ = 14 hours
Rationale: B. Half-life is calculated as t½ = (0.693 × Vd) / CL. For a Vd of 500 L and CL of 50 L/hr,
t½ = (0.693 × 500) / 50 = 6.93 hours, approximately 7 hours.
9. A patient with cirrhosis and ascites is prescribed a hydrophilic drug. How does the patient's
condition affect the volume of distribution of this drug?
A. It decreases
B. It increases
C. It remains unchanged
D. It becomes unpredictable
Rationale: B. In cirrhosis with ascites, there is an increase in total body water and extracellular
fluid volume, which increases the volume of distribution for hydrophilic drugs.
10. Which of the following is a primary factor that determines the bioavailability of an orally
administered drug?
A. Renal function
B. Hepatic first-pass metabolism
C. Volume of distribution
D. Protein binding
Rationale: B. First-pass metabolism refers to the metabolism of an oral drug by the liver
before it reaches systemic circulation, reducing the amount of active drug available and thus
lowering bioavailability.
11. What is the primary purpose of administering a loading dose of a medication?
A. To maintain steady-state levels
B. To rapidly achieve therapeutic drug concentrations
C. To reduce the risk of adverse effects
D. To prolong the drug's half-life
Rationale: B. A loading dose is given to rapidly achieve therapeutic plasma concentrations of a
drug, especially when the time to reach steady state is clinically unacceptable.
4|Page
NSG 533 ADVANCED PHARMACOLOGY EXAM 1WITH
VERIFIED ANSWERS DETAILED RATIONALES GRADED A+
NSG 533 Advanced Pharmacology Exam 1
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1–45)
1. A 68-year-old patient with heart failure and atrial fibrillation is being started on digoxin.
The nurse practitioner considers the patient's renal function because digoxin is primarily
eliminated renally. Which pharmacokinetic parameter is most directly affected by reduced
renal clearance, thereby increasing the risk of digoxin toxicity?
A. Volume of distribution
B. Hepatic metabolism
C. Elimination half-life
D. Protein binding
Rationale: C. Digoxin is excreted predominantly unchanged by the kidneys. Reduced renal
clearance prolongs the elimination half-life, causing drug accumulation and increased risk of
toxicity.
2. Which pharmacokinetic process is primarily affected by a patient's serum albumin levels?
A. Metabolism
B. Absorption
C. Distribution
D. Excretion
1|Page
,Page 2 of 74
Rationale: C. Distribution involves the transport of a drug by the bloodstream to its site of
action. Many drugs bind to plasma proteins like albumin, and only the unbound portion is
pharmacologically active. If albumin levels are low, the concentration of free drug increases,
potentially leading to toxicity.
3. When a drug is an inducer of the Cytochrome P450 (CYP) enzyme system, what is the most
likely clinical outcome for a co-administered substrate?
A. Prolonged half-life of the substrate drug
B. Increased plasma levels of the substrate drug
C. Decreased plasma levels of the substrate drug
D. Decreased rate of metabolism for the substrate drug
Rationale: C. Enzyme induction involves the stimulation of CYP enzymes, which increases the
metabolic capacity of the liver. This results in faster breakdown of substrate drugs, leading to
lower plasma concentrations and potentially subtherapeutic effects.
4. A drug with a high therapeutic index (TI) is generally considered:
A. Potentially toxic at standard doses
B. Relatively safe
C. Likely to cause significant side effects
D. Highly potent
Rationale: B. The therapeutic index is a ratio that compares the blood concentration at which
a drug becomes toxic to the concentration at which it is effective. A high therapeutic index
indicates a wide margin of safety between the therapeutic and lethal doses.
5. Which of the following describes a drug that binds to a receptor and produces a maximal
biological response?
A. Full Agonist
B. Antagonist
C. Partial Agonist
D. Inverse Agonist
Rationale: A. A full agonist binds to a receptor and produces a maximal biological response. A
2|Page
,Page 3 of 74
partial agonist produces a lower response, and an antagonist blocks the receptor without
activating it.
6. Pharmacokinetics is best defined as the study of:
A. The study of drug effects on the body; receptor binding, signal transduction, response, and
feedback
B. The study of drug movement throughout the body; absorption, distribution, metabolism, and
excretion
C. The study of drug toxicity; accumulation, sensitivity, idiosyncrasy, and tolerance
D. The study of drug interactions; potentiation, antagonism, synergism, and displacement
Rationale: B. Pharmacokinetics is derived from the Greek words "pharmakon" (drug) and
"kinesis" (motion). It encompasses the four basic processes of absorption, distribution,
metabolism, and excretion (ADME).
7. A 65-year-old male with chronic kidney disease (eGFR 30 mL/min) is prescribed a
medication that is primarily renally excreted. Which pharmacokinetic parameter is most
affected in this patient?
A. Bioavailability
B. Volume of distribution
C. Half-life
D. Onset of action
E. Protein binding
Rationale: C. Renal impairment directly affects drug excretion, leading to prolonged half-lives
and drug accumulation. Dose adjustments are often required.
8. A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (CL) of 50 L/hr. Which
of the following best describes the expected half-life (t½) and the clinical implication of such a
large Vd?
A. t½ = 5 hours
B. t½ = 10 hours
C. t½ = 7 hours
3|Page
, Page 4 of 74
D. t½ = 14 hours
Rationale: B. Half-life is calculated as t½ = (0.693 × Vd) / CL. For a Vd of 500 L and CL of 50 L/hr,
t½ = (0.693 × 500) / 50 = 6.93 hours, approximately 7 hours.
9. A patient with cirrhosis and ascites is prescribed a hydrophilic drug. How does the patient's
condition affect the volume of distribution of this drug?
A. It decreases
B. It increases
C. It remains unchanged
D. It becomes unpredictable
Rationale: B. In cirrhosis with ascites, there is an increase in total body water and extracellular
fluid volume, which increases the volume of distribution for hydrophilic drugs.
10. Which of the following is a primary factor that determines the bioavailability of an orally
administered drug?
A. Renal function
B. Hepatic first-pass metabolism
C. Volume of distribution
D. Protein binding
Rationale: B. First-pass metabolism refers to the metabolism of an oral drug by the liver
before it reaches systemic circulation, reducing the amount of active drug available and thus
lowering bioavailability.
11. What is the primary purpose of administering a loading dose of a medication?
A. To maintain steady-state levels
B. To rapidly achieve therapeutic drug concentrations
C. To reduce the risk of adverse effects
D. To prolong the drug's half-life
Rationale: B. A loading dose is given to rapidly achieve therapeutic plasma concentrations of a
drug, especially when the time to reach steady state is clinically unacceptable.
4|Page
